Materials and Methods
As in references S1-S3. Reagents for synthesis were purchased from Sigma-Aldrich, Fluka, Acros, Apollo Scientific and Bachem. Unless stated otherwise, column chromatography was carried out on silica gel 60 (SiliaFlash P60, . Analytical (TLC) and preparative thin layer chromatography (PTLC) were performed on silica gel 60 (Merck, 0.2 mm) and silica gel GF (SiliCycle, 1 mm), respectively. Chiral HPLC were performed on a LC-4000 from JASCO. Broad peaks are marked as br. 1 H and 13 C resonances were assigned with the aid of additional information from 1D and 2D NMR spectra (H, DEPT 135, HSQC and HMBC) . ESI-MS were performed on a ESI API 150EX and are reported as m/z (%). Accurate mass determinations S3 using ESI (HR ESI-MS) were performed on a Sciex QSTAR Pulsar mass spectrometer. addition of Et2O (50 mL) to precipitate the residue. The solid was filtered and washed with Et2O, the residue was then solubilized in CH2Cl2 (5 mL) and sat. NaHCO3 aqueous solution (2 mL) was added.
The aqueous phase was extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated in vacuo to afford 13 (150 mg, 82%) which was directly used in next step without further purification. To a solution of biotin (276 mg, 1.30 mmol) in DMF (10 mL) was added a solution of 13 (120 mg, 0.226 mmol) in DMF (10 mL), followed by HCTU (660 mg, 1.60 mmol) and DIPEA (600 µL Purification of the residue using silica gel column chromatography (CH2Cl2/MeOH 98:2) gave 
Catalysis
Stock solutions of substrates 1 (40 mM), 2 (400 mM) and biotinylated catalysts 5-9 (2 mM) were prepared in CD3CN. Solutions of substrates 1 should be freshly prepared otherwise decarboxylation product will be present.
Solutions were prepared by mixing successively streptavidin WT or mutants (100 µL, 2 mM, glycine buffer pH 3, 0.2 µmol), biotinylated ligands 5-9 (50 µL, 0.1 µmol), substrates 1 (25 µL, 1 µmol) and 2 (25 µL, 10 µmol) and stirred at 20 °C. After given time, 1 H NMR of the mixture, extracted with CDCl3 (0.6 mL), dried over Na2SO4, and filtered into NMR tube, was recorded. Integrals associated with the protons alpha to the carbonyl group of the addition product 3b (δ 3.01 ppm; d, 2H) were compared to the combined integration of all -OCH3 protons present in the substrates and products (i.e., from δ 3.84-3.79 ppm) to obtain conversion of the reaction.
For lower catalysts loading (1%, 0.1%), solutions of streptavidin S112Y (1 mM) and 8 (0.5 mM)
were prepared in glycine buffer (pH 3)/CD3CN 1:1 and diluted 10 or 100 times, followed by substrates 1 (5 mM) and 2 (50 mM). The reactions were followed by 1 H NMR spectroscopy and run until completion (72 h at 1% loading, 3 weeks for 0.1% loading).
The spectroscopic data obtained for product 3 were identical to the ones reported in the literature.
S7
Crude mixtures were analyzed by chiral HPLC, (i.e., column: CHIRALPAK ID column; mobile phase:
n-Hexane/i-PrOH 60/40, 0.5 mL/min, rt; detection: 254 nm, Figure S2 ). To determine absolute configuration of the product 3, chiral HPLC analysis was conducted under previously reported S15 conditions. The retention times found for the two enantiomers of 3 were comparable with the ones reported in the literature ( Figure S3 ).
Inhibiton experiments were carried by preparing solutions of streptavidin S112Y (1 mM), 8 (0.5 mM) and inhibitor (0.01-1M) followed by 1 and 2. Reactions were monitored by 1 H NMR spectroscopy.
Inhibition concentration IC50 and Hill coefficients n were determined by plotting the ee after completion of the reaction as a function of NO3 -concentration c and fitting them to the Hill equation (Eq S1)
where ee0 is the ee without NO3 -, eemin is the ee at NO3 -saturation, IC50 is the concentration of NO3 -required to inhibit 50% of the decrease in stereoselectivity and n is the Hill coefficient.
Titration of substrate 1 (0.01 M, CH3CN/H2O 1:1) by NaOH (0.1 M) was followed by pH meter.
All docking simulations were performed with GOLD (version 5.4) using the graphical interface Hermes 1.8.0, with method similar to that described in Robles et al. S8 Briefly, the method consisted in (i) docking of the catalyst covalently attached to the biotin in a biotin-loaded streptavidin crystal structure, (ii) reconstructing the entire cofactor with this conformation, and (iii) calculating the true interactions cofactor-host. First, the structure of the catalyst was generated using ChemBioDraw Ultra 14.0 and ChemBio3D Ultra 14.0: the biotin of cofactor 8 was deleted (up to the Namide bound to biotin, to afford an NDI flanked with diaminocyclohexane). This structure was optimized using the energy minimization (MM2 force field method) tool of ChemBio3D Ultra 14.0. The structure of the receptor consists of a dimer of streptavidin generated from the PDB structure 3PK2. S9 In this homotetrameric structure, streptavidin contains the biotinylated [Cp*Ir(Biot-p-L)Cl]. Using UCSF Chimera, S10 two S16 facing monomers, the solvent molecules and the salts were deleted. In the resulting dimer, both
[Cp*Ir(Biot-p-L)Cl] cofactors were deleted, except for one biotin (including the Cα atom which corresponds to the aromatic ipso-carbon from the spacer, Figure S8 ). During the docking procedure, a covalent restraint was set: the Cα atom of the linker of 8 is set to coincide with the Cα of the biotin in the streptavidin dimer. The 10 closest residues from the catalyst were kept flexible and can thus adopt a library of rotamers. These include the positions N49, N118, S112Y, K121 and L124 of both streptavidin monomers. From the resulting structure having the highest ChemScore, the coordinates of the atoms of both the biotin and the docked NDI are pooled in a single file, reconstructing the entire 8 with the minimized docked conformation. The interaction of this latter with the host (with rotamers selected from docking at the flexible positions) is then recalculated using the rescoring tool of GOLD 5.4 with ChemScore method.
The wild-type streptavidin and the various mutants screening herein were expressed and purified according to the previously reported protocol. S11, S12 S17 Figure S1 .
Supplementary Figures and Tables
1 H NMR spectra of a mixture of 1 (5 mM), 2 (50 mM) and artificial enzyme S112Y+8
(10% mol) in glycine buffer/CD3CN 1:1 at 20 °C extracted in CDCl3. The red arrow shows the formation of product, the blue one shows the consumption of 1, the green line shows where the decarboxylation product signal should be. S18 Figure S2 . Chiral HPLC traces obtained using Chiralpak ID column (n-hexane/i-PrOH 60:40, rt, 0.5 mL/min, 254 nm) for crude mixture obtained with S112Y+8 (A), WT+8 (B), S112Y+5 (C), K121F+8
(D). S19 Figure S3 . Chiral HPLC chromatogram obtained for product 3 using Chiralcel OD-H column (nhexane/i-PrOH 1:1, rt, 0.5 mL/min, 254 nm) for crude mixture obtained with streptavidin S112Y+8.
The retention times are in agreement with previously reported data: tR: (S) = 23.2 min, (R) =28.9 min (95% ee). (nm) Figure S5 . CD spectra recorded in MeOH of 5 (blue), 6 (green), 7 (red), 8 (yellow), 9 (black). Figure S9 . 1 H NMR spectrum of 11 in CDCl3. 
